बेनाज़ेप्रिल के इंटरैक्शन

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (एप्टिफिबाटाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not administer Lotensin within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2) ]. (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (क्लोज़ापिन लेबल, बॉक्स्ड चेतावनी)

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

ये दवाएं पोटैशियम का उत्सर्जन कम करती हैं; इनके साथ पोटैशियम सप्लीमेंट या नमक के विकल्प (सॉल्ट सब्स्टीट्यूट) जोड़ने से हाइपरकेलेमिया हो सकता है, जो दिल की धड़कन की लय पर असर डालता है। (NIH Office of Dietary Supplements, Potassium)

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (मेटोलाज़ोन लेबल, चेतावनियां)

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not administer Lotensin within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2) ]. (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Do not administer Lotensin within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2) ]. (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Lotensin is contraindicated in patients: who are hypersensitive to benazepril or to any other ACE inhibitor with a history of angioedema with or without previous ACE inhibitor treatment Lotensin is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (बेनाज़ेप्रिल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (अल्फुज़ोसिन लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (आर्मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (एटेनोलोल लेबल, चेतावनियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (एपोप्रोस्टेनोल लेबल, दवाओं के इंटरैक्शन)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (एल्टेप्लेज़ लेबल, दवाओं के इंटरैक्शन)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (एवानाफिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (एसेनापिन लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (एस्मोलोल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (ओलैंज़ापिन लेबल, चेतावनियां और सावधानियां)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive drugs: May cause symptomatic postural hypotension. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (कार्वेडिलोल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.7) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (टेराज़ोसिन लेबल, चेतावनियां और सावधानियां)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (टैक्रोलिमस लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (डाइएथिलप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (डुलोक्सेटिन लेबल, चेतावनियां और सावधानियां)

• Antihypertensive Drugs: Monitor blood pressure. (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां और सावधानियां)

Antihypertensives: Possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

ACE Inhibitors Benazepril: In healthy volunteers receiving single dose of 20 mg nifedipine ER and benazepril 10 mg, the plasma concentrations of benazeprilat and nifedipine in the presence and absence of each other were not statistically significantly different. (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (नियासिन लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (पोटैशियम आयोडाइड लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (प्राज़ोसिन लेबल, चेतावनियां)

In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (फेनेलज़िन लेबल, चेतावनियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (बिसोप्रोलोल लेबल, चेतावनियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Amphetamines may decrease the hypotensive effect of antihypertensives. (बेंज़फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (ब्रोमफेनिरामिन, स्यूडोएफेड्रिन और डेक्सट्रोमेथॉर्फन लेबल, दवाओं के इंटरैक्शन)

Use caution in patients taking antihypertensive medications. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs: Monitor blood pressure. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (मिर्टाज़ापिन लेबल, चेतावनियां और सावधानियां)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (मेकामाइलामिन लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (रियोसिगुआट लेबल, चेतावनियां और सावधानियां)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Lithium: Symptoms of lithium toxicity ( 7.6 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (लैंथेनम लेबल, दवाओं के इंटरैक्शन)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (वार्डेनाफिल लेबल, दवाओं के इंटरैक्शन)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Agents Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. (वेरापामिल लेबल, दवाओं के इंटरैक्शन)

In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

Table 2: Drugs that Potentiate Cyclophosphamide Toxicities Toxicity Drugs Increased hematotoxicity and/or immunosuppression ● ACE inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity… (साइक्लोफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (साइक्लोस्पोरिन लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.7) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (सिलोडोसिन लेबल, चेतावनियां और सावधानियां)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (सिल्डेनाफिल लेबल, चेतावनियां और सावधानियां)

Initiate and/or adjust antihypertensive therapy as appropriate. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (इकाटिबेंट लेबल, दवाओं के इंटरैक्शन)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (इसराडिपिन लेबल, दवाओं के इंटरैक्शन)

Use with Angiotensin-Converting Enzyme Inhibitors: The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia. (एज़ाथियोप्रिन लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (एफेड्रिन लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (क्लोरप्रोमाज़िन लेबल, चेतावनियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (ट्राइफ्लुओपेराज़िन लेबल, सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (डेसिप्रामिन लेबल, चेतावनियां)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (नाइट्रोप्रुसाइड लेबल, चेतावनियां)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (निसोल्डिपिन लेबल, दवाओं के इंटरैक्शन)

The antihypertensive action of guanethidine and similar agents may be blocked. (नॉरट्रिप्टिलीन लेबल, चेतावनियां)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (प्रोक्लोरपेराज़िन लेबल, सावधानियां)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (प्रोट्रिप्टिलीन लेबल, चेतावनियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

…specific interaction studies were not performed, PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory… (फिनास्टेराइड लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (ब्यूटॉर्फेनॉल लेबल, चेतावनियां)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (मिथाइलडोपा लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (मेक्सिलेटिन लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (मेटोप्रोलोल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline,… (सिडोफोविर लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (हाइड्रालाज़िन लेबल, दवाओं के इंटरैक्शन)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)

Symptoms have not been relieved by antihistamines in these situations. (बेनाज़ेप्रिल लेबल, चेतावनियां और सावधानियां)